We interpret the clinical and mechanistic data obtained for different agents that enable weight loss and glucose control for the treatment of obesity and type 2 diabetes mellitus, respectively, by activating or blocking GIPR signalling, including the GIPRGLP1R co-agonist tirzepatide, as well as the GIPR antagonistGLP1R agonist AMG-133
The injection can be done at any time of day, with or without food, allowing flexibility to fit into your schedule
Tirzepatide (MOUNJARO) Pronounced: tir ZEP a tide / mown JAHR OH Mnemonic: Tear zeppelin (over) Mount (Kiliman)jaro Year of release: 2022 Cost: $1060 / mo FDA-approved for: Type 2 diabetes Mechanism: dual GLP-1/GIP receptor agonist Available doses: 2.5 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg, 15 mg (weekly subcutaneous injection) Dynamic interactions: Glucose lowering Kinetic interactions: Delayed gastric emptying, otherwise none significant in a bubble Tirzepatide (Mounjaro) is the first twincretin for type 2 diabetes
Her goal is to empower patients through knowledge, safety, and personalized care.
While you may feel less active while fighting an infection, the medication continues to work on your appetite and blood sugar